Conagra Brands Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Conagra Brands (CAG) is set to report its first-quarter earnings on October 1, with analysts projecting a significant decline in EPS to 33 cents from 53 cents year-over-year and revenue of $2.62 billion, down from $2.79 billion. This anticipated underperformance follows worse-than-expected fourth-quarter results and a lowered FY26 adjusted EPS guidance, contributing to a 0.8% share price dip to $18.04 on Monday. Analyst sentiment remains largely cautious, with several recent price target cuts despite maintained neutral-equivalent ratings.

Analysis

Conagra Brands (CAG) faces a challenging outlook ahead of its first-quarter earnings release on October 1, with consensus analyst expectations pointing to a significant contraction. Projections indicate a 37.7% year-over-year decline in quarterly earnings to 33 cents per share and a 6.1% drop in revenue to $2.62 billion from $2.79 billion a year prior. This anticipated weakness is not an isolated event, as it follows the company's worse-than-expected fourth-quarter results and a disappointing FY26 adjusted EPS guidance issued on July 10. The market has reacted to this negative trajectory, with shares recently declining 0.8% to close at $18.04. Analyst sentiment is predominantly neutral, with firms like Wells Fargo, UBS, and Evercore ISI maintaining 'Equal-Weight' or 'In-Line' ratings. However, this stance is accompanied by a bearish undertone, as most analysts have recently trimmed their price targets, with both Wells Fargo and UBS cutting their targets to $19. A single outlier, Morgan Stanley, boosted its price target to $21 but maintained its 'Equal-Weight' rating, indicating a complex, but largely cautious, institutional view.

Key Decisions for Investors

• Given the established negative trend and prior guidance cuts, investors should scrutinize the upcoming Q1 report for any signs of stabilizing revenue or margins, as the key focus will be on management's forward-looking commentary.
• The overwhelmingly neutral analyst ratings, paired with numerous price target reductions, suggest a 'hold' or 'wait-and-see' approach is prudent until the company demonstrates a tangible reversal of its declining performance.
• Consider the low expectations as a potential setup for a positive surprise, but weigh this against the significant fundamental headwinds, including recent underperformance and a history of downward guidance revisions.